Press Room
Stay informed with the latest updates from Teoxane. From product innovations to scientific breakthroughs and global milestones, explore our official press releases and discover how we continue to shape the future of aesthetic medicine and skincare.
Teoxane is pleased to announce its participation in IMCAS 2025, taking place from January 30 to February 1, 2025, at the Palais des Congrès in Paris.
On this occasion, TEOXANE will highlight the 10th anniversary of its flagship RHA® (Resilient Hyaluronic Acid) collection, a symbol of a decade of innovation and scientific progress.
<Press Release> < Communiqué> < Pressemitteilung> < Comunicato Stampa> < Comunicado De Prensa>
At AMWC 2025 in Monaco, Teoxane unveils R-ENERGY, a multidimensional approach to skin quality combining injectables and dermocosmetics—designed to meet the growing demand for radiant, healthy-looking skin at every stage of life.
< Press Release> < Communiqué> < Pressemitteilung> < Comunicato Stampa> <Comunicado De Prensa>
Teoxane, a recognized leader in the field of dermal fillers and hyaluronic acid-based dermocosmetics, has been honored for the second consecutive year at the "Switzerland's Best Managed Companies" awards ceremony, organized by Deloitte in Zurich, on June 27th, 2024
< Press Release> < Communiqué> < Pressemitteilung> < Comunicato Stampa> < Comunicado De Prensa>
Teoxane, leader in the field of hyaluronic acid-based aesthetic solutions, announces the launch of its new generation of syringes. Designed to offer an optimal injection experience for practitioners, these syringes combine enhanced features with a premium design, meeting the needs of the most demanding healthcare professionals.
< Press Release> < Communiqué> < Pressemitteilung> < Comunicato Stampa> < Comunicado De Prensa>
Teoxane announces the publication of new real-world clinical data on TEOSYAL® PureSense Redensity 2 (R2), reinforcing its efficacy and safety for periorbital rejuvenation.
The EYELIGHT study evaluated 136 subjects across multiple centers in the UK and France, providing valuable clinical insights into the use of Redensity 2 across the periorbital region, including the tear trough, palpebromalar groove, crow’s feet, outer canthus, and brow areas.
Teoxane is pleased to announce the publication of the SKINQARE study in the Aesthetic Surgery Journal, highlighting the benefits of a sequential approach using two hyaluronic acid injectables to improve overall skin quality.
Conducted across multiple centers in Spain, the study shows that combining RHA® 1 for skin beautification with Redensity 1 for redensification delivers firmer, smoother, and more hydrated skin, with sustained improvements up to 5 months.
Teoxane announces the publication of new U.S. clinical data in the Aesthetic Surgery Journal demonstrating the favorable safety profile and long-lasting, natural-looking results of RHA® 3 for lip augmentation.
This pivotal randomized, controlled trial enrolled 202 subjects and showed sustained improvements in lip fullness, high patient satisfaction, and strong safety outcomes over 52 weeks, supporting the FDA authorization of RHA® 3 for lip volumization.